The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. https://jadaftvx093593.blogacep.com/44565014/glp-3-retatrutide-a-comparative-analysis